Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
The study marks victory against Soliris, but Apellis could still find the market hard to crack.
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.